Popular Articles

Government Must Take Care Not To Raise Expectations Beyond What NHS Can Deliver - The King's Fund, UK
Commenting on the health announcements contained in Building Britain"s Future, The King"s Fund chief executive Niall Dickson said: "The idea that patients should have a right to certain standards of treatment is a good one and the government should be congratulated on reducing the number of central targets, some of which were hard to justify. However, we do need to be clear that many of the "rights" set out in the Prime Minister"s announcement are currently "must do"s" for the NHS. For example, the four hour maximum wait in accident and emergency, the 18 week wait for hospital treatment and health checks for 40 year olds are all already in operation.
pharmacy online
New Insights Into Health And Environmental Effects Of Carbon Nanoparticles
A new study raises the possibility that flies and other insects that encounter nanomaterial "hot spots," or spills, near manufacturing facilities in the future could pick up and transport nanoparticles on their bodies, transferring the particles to other flies or habitats in the environment. The study on carbon nanoparticles - barely 1/5,000th the width of a human hair - is scheduled for the Aug. 15 issue of ACS" Environmental Science & Technology, a semi-monthly journal.
News of the day
Matthew Lehman Of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar
In designing and conducting clinical trials, it is critical to meet FDA objectives while preventing program "drift," according to Matthew Lehman, chief operating officer of SPRI Clinical Trials-Global, LLC in his remarks at a recent seminar for biotechnology companies.
Medical Devices

Artificial Liver For Drug Tests

If you have hay fever, headaches or a cold, it"s only a short way to the nearest chemist. The drugs, on the other hand, can take eight to ten years to develop. Until now animal experiments have been an essential step, yet they continue to raise ethical issues. "Our artificial organ systems are aimed at offering an alternative to animal experiments," says Professor Heike Mertsching of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart. "Particularly as humans and animals have different metabolisms. 30 per cent of all side effects come to light in clinical trials." The test system, which Professor Mertsching has developed jointly with Dr. Johanna Schanz, should in future give pharmaceutical companies greater security and shorten the path to new drugs. Both researchers received the "Human-centered Technology" prize for their work. "The special feature, in our liver model for example, is a functioning system of blood vessels," says Dr. Schanz. "This creates a natural environment for cells." Traditional models do not have this, and the cells become inactive. "We don"t build artificial blood vessels for this, but use existing ones - from a piece of pig"s intestine." All of the pig cells are removed, but the blood vessels are preserved. Human cells are then seeded onto this structure - hepatocytes, which, as in the body, are responsible for transforming and breaking down drugs, and endothelial cells, which act as a barrier between blood and tissue cells. In order to simulate blood and circulation, the researchers put the model into a computer-controlled bioreactor with flexible tube pump, developed by the IGB. This enables the nutrient solution to be fed in and carried away in the same way as in veins and arteries in humans. "The cells were active for up to three weeks," says Dr. Schanz. "This time was sufficient to analyze and evaluate the functions. A longer period of activity is possible, however." The researchers established that the cells work in a similar way to those in the body. They detoxify, break down drugs and build up proteins. These are important pre-conditions for drug tests or transplants, as the effect of a substance can change when transformed or broken down - many drugs are only metabolized into their therapeutic active form in the liver, while others can develop poisonous substances. The researchers have demonstrated the basic possibilities for use of the tissue models - liver, skin, intestine and windpipe. At the moment, the test system is being examined. Within two years it could provide a safer alternative to animal experiments. Heike Mertsching Fraunhofer-Gesellschaft


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):